Lipoteichoic acid (LTA) (LTA)

Lipoteichoic acid (LTA) is a major cell wall component of Gram-positive bacteria, such as Staphylococcus aureus and Streptococcus pneumoniae, consisting of a poly(glycerophosphate) chain anchored to the cytoplasmic membrane by a glycolipid (Ginsburg, 2002, PubMed ID: 12410053). It plays a critical role in bacterial physiology, including the regulation of autolytic enzymes, ion homeostasis (specifically sequestering magnesium ions), and providing structural integrity to the cell wall (Kang et al., 2014, PubMed ID: 24901451). As a potent pathogen-associated molecular pattern (PAMP), LTA is recognized by the host's innate immune system through Toll-like receptor 2 (TLR2) and CD14, triggering a pro-inflammatory cascade that can lead to sepsis and septic shock (Rockel & Hartung, 2012, PubMed ID: 22828215). In clinical development, LTA has been targeted by monoclonal antibodies like pagibaximab to neutralize its inflammatory effects and prevent staphylococcal infections in high-risk populations such as neonates (Weisman et al., 2011, PubMed ID: 21402687). Despite its importance as a target, therapeutic challenges include the high variability of LTA structure across species and the potential for massive LTA release during antibiotic-induced bacterial lysis, which can exacerbate inflammatory responses.

Other names

LTAGram-positive bacterial cell wall polymerGlycerol phosphate polymer

Neutralization of the molecule to prevent TLR2-mediated inflammatory signaling and inhibition of bacterial cell wall assembly and maintenance.